Derstine Timothy, Lanocha Karl, Wahlstrom Carl, Hutton Todd M
SunPointe Health, State College, PA, USA.
Ann Clin Psychiatry. 2010 Nov;22(4 Suppl):S4-11.
Another option for managing major depressive disorder (MDD) became available in October 2008 with the Food and Drug Administration's (FDA) market clearance of NeuroStar TMS (transcranial magnetic stimulation) Therapy System. A panel of psychiatrists who have been treating patients with NeuroStar TMS Therapy in their clinics assembled for a virtual roundtable discussion regarding their experiences. In this supplement, the panel addresses the following issues: the FDA-cleared indication for use of NeuroStar TMS Therapy; logistic and staffing considerations in the outpatient setting; selecting the right patient for TMS Therapy; talking with patients and family about TMS Therapy. To give the overview a meaningful context, each panelist shares a personal account of a patient case, describing the treatment course and outcomes achieved with TMS Therapy.
2008年10月，随着美国食品药品监督管理局（FDA）批准NeuroStar经颅磁刺激（TMS）治疗系统上市，重性抑郁障碍（MDD）的治疗又多了一种选择。一组在诊所使用NeuroStar TMS治疗系统治疗患者的精神科医生齐聚一堂，参加了一场关于他们治疗经验的虚拟圆桌讨论。在本增刊中，该小组讨论了以下问题：FDA批准的NeuroStar TMS治疗系统的适用症；门诊环境中的后勤和人员配备考虑因素；选择合适的TMS治疗患者；与患者及其家属谈论TMS治疗。为了让概述有一个有意义的背景，每位小组成员都分享了一个患者病例的个人经历，描述了TMS治疗的疗程和取得的效果。
